About Beta-chimaerin
Beta-chimaerin (CHN2) is a protein
from Homo sapiens identified by UniProt accession
P52757, 468 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Beta-chimaerin |
| UniProt accession | P52757 |
| Gene | CHN2 |
| Organism | Homo sapiens |
| Length | 468 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- gut microbiome measurement · score 0.32
- balding measurement · score 0.31
- triglyceride measurement · score 0.27
- cortical surface area measurement · score 0.24
- cortical thickness · score 0.24
- PHF-tau measurement · score 0.21
- neurofibrillary tangles measurement · score 0.21
- hair shape measurement · score 0.21
- brain measurement · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P52757-F1 | alphafold | PREDICTED | 84.71 | — |
Amino-acid sequence (468 residues)
MAASSNSSLS GSSVSSDAEE YQPPIWKSYL YQLQQEAPRP KRIICPREVE NRPKYYGREF HGIISREQAD ELLGGVEGAY ILRESQRQPG CYTLALRFGN QTLNYRLFHD GKHFVGEKRF ESIHDLVTDG LITLYIETKA AEYISKMTTN PIYEHIGYAT LLREKVSRRL SRSKNEPRKT NVTHEEHTAV EKISSLVRRA ALTHNDNHFN YEKTHNFKVH TFRGPHWCEY CANFMWGLIA QGVRCSDCGL NVHKQCSKHV PNDCQPDLKR IKKVYCCDLT TLVKAHNTQR PMVVDICIRE IEARGLKSEG LYRVSGFTEH IEDVKMAFDR DGEKADISAN VYPDINIITG ALKLYFRDLP IPVITYDTYS KFIDAAKISN ADERLEAVHE VLMLLPPAHY ETLRYLMIHL KKVTMNEKDN FMNAENLGIV FGPTLMRPPE DSTLTTLHDM RYQKLIVQIL IENEDVLF
Explore Beta-chimaerin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets